期刊文献+

The difference between multi-drug resistant cell line H460/Gem and its parental cell NCI-H460

吉西他滨耐药细胞系H460/Gem及其亲代细胞NCI-H460之间的不同(英文)
下载PDF
导出
摘要 Objective: To discuss the difference between multi-drug resistant cell line H460/Gem and its parental cell NCl-H460 on the basis of establishment of human gemcitabine-resistant cell line H460/Gem so as to elaborate the possible mechanisms of gemcitabine resistance. Methods: Human gemcitabine-resistant non-small cell lung cancer cell line H460/Gem was established by 2/3 clinical serous peak concentration gemcitabine intermittent selection from its parental cell human large cell lung carcinoma cell line NCl-H460 which was sensitive to gemcitabine. During the course of inducement, we had monitored their morphology, checked their resistance indexes and resistant pedigree by MTT method, gathered their growth curves and calculated their doubling time, examined their DNA contents and cell cycles by FCM; at the same time, we had measured its expressions of P53, EGFR, c-erb-B-2, PTEN, PCNA, c-myc, VEGF, MDR-1, Bcl-2, nm23, MMP-9, TIMP-1, CD44v6 proteins via immunocytochemistry staining, RRM1 and ERCC1 mRNA by real-time fluorescent quantitative-PCR. Results: The resistance index of H460/Gem' cells (the deputy of cells in the process of inducement) to gemcitabine was 1.201, and the cell line also exhibited cross-resistance to paclitaxol, fluorouraci, etoposide, cisplatin and oxaliplatin, but kept sensitivity to vinorelbine and taxotere. The doubling time of H460/Gem' cells was longer and figures in G0-G1 phase was decreased than that of NCl-H460 cells. Compared with NCl-H460 cells, H460/Gem' cells had achieved TIMP-1 protein expression emerged, nm23 protein expression enhanced, VEGF and MMP-9 protein expressions reduced, and CD44v6, P53 protein expressions vanished, but expressions of EGFR, c-erb-B-2, PTEN, PCNA, c-myc, MDR-1, Bcl-2 proteins and RRM1, ERCC1 mRNA changed trivially. The resistance index of H460/Gem cells to gemcitabine was 1.644, and the ceil line also exhibited cross-resistance to fluorouraci, cisplatin and oxaliplatin, but kept sensitivity to paclitaxol, vinorelbine, taxotere, and etoposide. The doubling time of H460/Gem cells was longer and figures in G0-G1 phase was decreased than those of NCl-H460 cells. The farther studies indicated that, compared with NCl-H460 cells, the expressions of MDR-1, nm23 and Bcl-2 proteins in H460/Gem cells had been enhanced, c-erb-B-2 protein expression emerged, P53, MMP-9 and VEGR protein expression had been weakened, but the changes of PTEN, PCNA, c-myc, TIMP-1, EGFR, CD44v6 protein, RRM1 mRNA and ERCC1 mRNA expressions were trivial. Furthermore, compared with its parental cells, H460/Gem cells were mixed with giant cells of different sizes that were larger and more irregular. Conclusion: The human gemcitabine-resistant non-small cell lung cancer cell line H460/Gem had achieved multi-drug resistance and great changes of biological characters compared with its parental cells. And these changes possibly participated in the formation of multidrug resistance.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第11期615-619,共5页 中德临床肿瘤学杂志(英文版)
基金 Capital Medical Developmental Foundation (No. 2003-3028)
关键词 multi-drug resistance non-small cell lung cancer (NSCLC) gene GEMCITABINE 药物抗性 非小细胞肺癌 基因 遗传性
  • 相关文献

参考文献12

  • 1Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004.64: 3761-3766.
  • 2Situ ZQ, Wu JZ. Cell culture. Revised edition. Xian: International Books Publishing Company, 2004. 241-243.
  • 3Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer, 2005, 47: 183-192.
  • 4Smid K, Bergman AM, Eijk PP, et al. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids, 2006, 25: 1001-1007.
  • 5Hoon DS, Kitago M, Kim J, et al. Molecular mechanisms of metastasis. Cancer Metastasis Rev, 2006, 25: 203-220.
  • 6Krishnan K, Khanna C, Helman LJ. The molecular biology of pulmonary metastasis. Thorac Surg Clin, 2006, 16: 115-124.
  • 7Sun Y, P53 and its downstream proteins as molecular targets of cancer. Mol Carcinog, 2006, 45: 409-415.
  • 8Iniesta P, Moran-A, De Juan C, et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep, 2007, 17: 217-223.
  • 9Bergman AM, Eijk PP, Ruiz van Haperen VW, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribo- nucleotide reductase subunit M1 as the major determinant. Cancer Res, 2005, 65: 9510-9516.
  • 10Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol, 2006, 24: 4731-4737.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部